Reducing atherothrombotic events in high-risk patients: recent data on therapy with statins and fatty acids

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Nutritional Science

Background:

• Traditional treatment for atherosclerotic coronary heart disease (CHD) emphasizes "critical" stenoses.
• This approach may be less effective in reducing morbidity and mortality compared to therapies targeting plaque stabilization and thrombosis.
• Revascularization effectively treats high-grade stenoses but leaves numerous smaller, event-causing plaques untreated.

Purpose of the Study:

• To evaluate the effectiveness of plaque-stabilizing therapies in reducing morbidity and mortality in CHD.
• To compare the benefits of statin therapy and dietary modifications with traditional approaches.

Main Methods:

• Review of recent clinical trial data on 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) therapy.
• Analysis of studies on dietary fat composition modification, including monounsaturated and omega-3 polyunsaturated fatty acids.
• Assessment of plaque stabilization benefits within one year for high-risk patients.

Main Results:

• Statin therapy and dietary fat modification demonstrate the ability to reduce clinical events in CHD.
• Statin therapy shows potential for plaque stabilization in high-risk patients within a year.
• Increased dietary intake of monounsaturated or omega-3 polyunsaturated fatty acids may offer additional benefits.

Conclusions:

• Statin therapy and specific dietary changes can improve morbidity and mortality in CHD.
• These interventions modify the underlying atherothrombotic disease process, offering a more comprehensive treatment strategy.
• Atherothrombotic disease modification is key to improving outcomes in coronary heart disease.